Clinical Trials Sponsored by Eiger BioPharmaceuticals

Total 724 results

Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Eiger BioPharmaceuticals

Terminated

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Hepatitis D

United States
Eiger BioPharmaceuticals

Active, not recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

Hepatitis Delta Virus

United States, France, Belgium, Spain, Italy, Turkey, Bulgaria, Germany, Israel, Romania, Georgia, Moldova, Republic of
Eiger BioPharmaceuticals

Terminated

Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY2)

Pulmonary Arterial Hypertension

United States, Canada
Eiger BioPharmaceuticals

Completed

Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (CLEAN-1)

Hepatitis C
Eiger BioPharmaceuticals

Withdrawn

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV (LOWR-5)

Chronic Delta Hepatitis
Eiger BioPharmaceuticals

Completed

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)

Hepatitis Delta Virus

United States, Belgium, Spain, Greece, Canada, Italy, Romania, Germany, Israel, Bulgaria, Taiwan, Turkey, Pakistan, Sweden, Ukraine, New Zealand, Russian Federation, United Kingdom, Moldova, Republic of, France, Mongolia, Switzerland
Eiger BioPharmaceuticals

Completed

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY)

Pulmonary Arterial Hypertension

United States, Canada
Eiger BioPharmaceuticals

Completed

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Lymphedema

United States, Australia
Eiger BioPharmaceuticals

Completed

Lonafarnib With and Without Ritonavir in HDV (LOWR-1) (LOWR-1)

Chronic Hepatitis D Infection

Turkey
Eiger BioPharmaceuticals

Completed

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia (PREVENT)

Postbariatric Hypoglycemia

United States
Eiger BioPharmaceuticals

Approved for marketing

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

Progeria | HGPS
Eiger BioPharmaceuticals
Ankara University

Completed

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) (LOWR-2)

Chronic Hepatitis D Infection

Turkey
Eiger BioPharmaceuticals
Hannover Medical School

Completed

Titrating-Dose of Lonafarnib in Combination With Ritonavir (LOWR-4)

Chronic Delta Hepatitis
Johns Hopkins University
Eiger BioPharmaceuticals

Terminated

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection (PROTECT)

Sars-CoV-2 Infection

United States
Tracey McLaughlin
Eiger BioPharmaceuticals

Completed

Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

Post Bariatric Hypoglycemia

United States
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Raymond Chung
Eiger BioPharmaceuticals

Terminated

Pegylated Interferon Lambda Treatment for COVID-19

COVID-19 | COVID

United States
Dr. Tracey McLaughlin, MD
Eiger BioPharmaceuticals

Completed

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Acquired Hyperinsulinemic Hypoglycemia

United States
Icahn School of Medicine at Mount Sinai
Eiger BioPharmaceuticals

Withdrawn

Interferon Lambda Therapy for COVID-19

SARS-CoV-2
Cardresearch
McMaster University; Eiger BioPharmaceuticals; Cytel Inc.; Fastgrants; RainWater...

Recruiting

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Covid19 | SARS-Associated Coronavirus

Brazil
Boston Children's Hospital
Merck Sharp & Dohme LLC; Schering-Plough; Eiger BioPharmaceuticals

Active, not recruiting

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Progeria

United States
Eiger Group International, Inc.

Unknown

Clemizole HCl for Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Turkey
Duke University
Eigen

Recruiting

Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking ((TRUS))

Uterine Cancer

United States
Angitia Biopharmaceuticals

Recruiting

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Recruiting

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Rheumatoid Arthritis

United States
Angitia Biopharmaceuticals

Completed

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Completed

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Arthritis, Rheumatoid

United States
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) (COMPASS)

Chronic Kidney Diseases | Iron Deficiency Anemia

United States
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Navidea Biopharmaceuticals

Withdrawn

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Kythera Biopharmaceuticals

Completed

Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)

Submental Fullness

United States, Canada
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Anemia of Chronic Kidney Disease

United States
Keryx Biopharmaceuticals

Completed

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Iron Deficiency Anemia | Iron Deficiency

United States
Navidea Biopharmaceuticals

Withdrawn

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Navidea Biopharmaceuticals

Unknown

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Dementia | Alzheimer's Disease

United States
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

Lipoma

United States
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Kythera Biopharmaceuticals

Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Evaluation of the Effect of ATX-101 on QT/QTc Intervals (ATX-101-11-24)

Healthy

United States
Nabi Biopharmaceuticals

Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Staphylococcal Infections
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
OMRIX Biopharmaceuticals

Completed

Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy (Fleece)

Nephrectomy | Hemostatic Techniques

Israel
Nabi Biopharmaceuticals

Completed

StaphVAX in Cardiovascular Surgery Patients

Cardiovascular Diseases | Staphylococcal Infections | Cardiovascular Surgical Procedures

United States
XTL Biopharmaceuticals

Unknown

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Israel
Nabi Biopharmaceuticals

Completed

Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis

Kidney Failure, Chronic | Staphylococcal Infections
Keryx Biopharmaceuticals

Recruiting

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Hyperphosphatemia Related to Chronic Kidney Disease

United States

Clinical Trials Sponsored by Eiger BioPharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations